Active Ingredient(s): Guselkumab
FDA Approved: * July 13, 2017
Pharm Company: * JANSSEN BIOTECH
Category: Immunosuppressive

Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis.[5][6] Contents 1 Medical uses 2 Adverse effects 3 Pharmacology 3.1 Mechanism of action 3.2 Pharmacokinetics 4 Commercialization 4.1 Cost 4.2 Research and development 5 References 6 External links Medical uses Guselkumab is indicated to treat moderate to severe plaque psoriasis, and psoriatic arthritis in adults.... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Tremfya 100 mg/ml Subcutaneous Injection
NDC: 57894-640
Janssen Biotech, Inc.